Pulmonary Hypertension (PH) Biorepository for Translational Research

Study Description: This study aims to establish a biorepository based on the World Symposium Pulmonary Hypertension (PH) Groups 1-5. In the future, IRB approved protocols may use these blood samples to discover novel, biologically relevant, non-invasive PH biomarkers. In combination with clinical data these potential biomarkers will be used to distinguish PH groups, elucidate underlying molecular phenotypes, predict clinically relevant outcomes, as well as discriminate healthy (healthy subjects will not be enrolled under this protocol) from PH disease states, and differentiate patients with PH from patients without PH. To this end, multimodal genomic, metabolomic, and proteomic assays will eventually be developed and used. Objectives: Primary: Develop a multi-center biorepository of patients suspected of or diagnosed with PH Group 1-5. Secondary: Collect the specific data attributes that may be used in the future to determine whether multimodal genomic, metabolomic or proteomic biomarkers, in combination with clinical data, can: -Elucidate molecular phenotypes that distinguish between patients across PH groups Predict clinically relevant outcomes (i.e., disease severity, disease progression, response to therapy, transplant free survival).

* INCLUSION CRITERIA: * Provision of signed and dated informed consent form * Males and females aged \>=18 years old * Suspected of or diagnosed with PH * Able to understand and willing to sign a written informed consent document EXCLUSION CRITERIA: Any individual who does not meet all inclusion criteria or is deemed by the local investigator not to be a blood draw candidate will be excluded from participating in this study.